Search
Research
Rheumatic Fever Follow-Up Study (RhFFUS) protocol: A cohort study investigating the significance of minorIn Australia, rheumatic heart disease (RHD) is almost exclusively restricted to Aboriginal Australian and Torres Strait Islander people with children being...
Research
The future of acute rheumatic fever and rheumatic heart disease in AustraliaGlobally, ARF and RHD cause more than a quarter of a million deaths and substantial disability each year.
News & Events
Partnering with communities to reduce rheumatic heart disease in the KimberleyThe Kimberley has the highest rates of rheumatic heart disease (RHD) in Western Australia – but through the establishment of a new community-led, research-backed project known as END RHD Communities, there’s hope this will change.
Research
RHD ActionRosemary Sophie Jonathan Wyber La Vincente Carapetis AM MBChB MPH FRACGP PhD BPsych (Hons) MAppEpi PhD AM MBBS FRACP FAFPHM PhD FAHMS Senior Research
Research
Development of methods to rapidly track pathogen and antibiotic resistance profiles from skin sores in Northern Australia (Hot North)Asha Jonathan Marianne Tim Bowen Carapetis AM Mullane Barnett BA MBBS DCH FRACP PhD GAICD FAHMS OAM AM MBBS FRACP FAFPHM PhD FAHMS BSc (OT) PhD Head,
Research
END RHD Community Project - Kimberley (Rheumatic Fever Strategy)Dylan John Jonathan Rosemary Barth Jacky Carapetis AM Wyber B.Tech, MPH, PhD AM MBBS FRACP FAFPHM PhD FAHMS MBChB MPH FRACGP PhD Honorary Research
Research
Honey as a potential topical treatment for skin infections: a literature reviewAsha Glenn Marianne Bowen Pearson Mullane BA MBBS DCH FRACP PhD GAICD FAHMS OAM BA (Education) PhD Candidate BSc (OT) Head, Healthy Skin and ARF
Research
Improving delivery of secondary prophylaxis for rheumatic heart diseaseJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal DiseasesVaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities.